EU Commission approves Gilead Trodelvy-Keytruda combo for first-line PD-L1+ metastatic TNBC
GILD•EU approval expands Trodelvy use in metastatic TNBC
The European Commission granted marketing authorization for Trodelvy with Merck’s Keytruda in first-line metastatic triple-negative breast cancer with PD-L1 CPS 210.
The decision expands Gilead’s Trodelvy use across PD-L1 status in Europe, including monotherapy for patients not eligible for PD-1 or PD-L1 inhibitors.
Phase 3 trial showed lower risk of progression or death
Phase 3 ASCENT-04/KEYNOTE-D19 showed a 35% lower risk of disease progression or death versus standard chemotherapy with Keytruda.
